Pancreatic CancerPhase 3NCT00075686
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase 3 study testing cetuximab and gemcitabine hydrochloride in people with Pancreatic Cancer, run by SWOG Cancer Research Network at 389 sites in 2 countries.
Trial summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer
- What is being tested?
- cetuximab and gemcitabine hydrochloride
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 766 participants
- Where
- 389 sitesin 2 countries
- Study dates
- Jan 2004to Apr 2009
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically* or cytologically confirmed pancreatic adenocarcinoma meeting 1 of the following criteria:
- Locally advanced unresectable disease
- Distant metastatic disease NOTE: If diagnosis is based on a metastatic site the histology must be compatible with pancreatic cancer
- Measurable or nonmeasurable disease by x-ray, scan, or physical examination
- Tumor tissue must be submitted for evaluation of epidermal growth factor receptor expression before study entry
- None of the following tumor types are allowed:
- Endocrine tumors
- Lymphoma of the pancreas
- Ampullary cancer
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Zubrod 0-2
Life expectancy
- At least 3 months
Hematopoietic
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 2.0 times upper limit of normal (ULN)
- SGOT or SGPT no greater than 2.5 times ULN
Renal
- Creatinine no greater than 2.0 mg/dL
Cardiovascular
- No significant history of cardiac disease
- No uncontrolled hypertension
- No unstable angina
- No uncontrolled arrhythmia
- No congestive heart failure
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- HIV negative
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer that is currently in remission
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior immunotherapy for advanced pancreatic cancer
- No prior cetuximab or other therapy that targets the epidermal growth factor pathway
- No prior chimerized or murine monoclonal antibody therapy
- No other concurrent anticancer immunotherapy
Chemotherapy
- At least 6 months since prior adjuvant chemotherapy
- No prior chemotherapy or chemoradiotherapy for advanced pancreatic cancer
- No prior gemcitabine
- No other concurrent anticancer chemotherapy
Endocrine therapy
- No prior hormonal therapy for advanced pancreatic cancer
- No concurrent anticancer hormonal therapy
Radiotherapy
- See Chemotherapy
- At least 28 days since prior radiotherapy and recovered
- Prior palliative radiotherapy to metastatic sites allowed
- No concurrent anticancer radiotherapy, including whole brain radiotherapy for progressive disease (i.e., CNS metastasis)
Surgery
- At least 14 days since prior pancreatic cancer surgery and recovered
Other
- No other concurrent anticancer therapy
Trial locations and contacts
389 sites in 2 countries.
307 sites in 2 countries
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Akron City Hospital
Akron, Ohio, 44309-2090
New York Oncology Hematology, PC - Albany
Albany, New York, 12208
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87131-5636
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Harrington Cancer Center
Amarillo, Texas, 79106
American Fork Hospital
American Fork, Utah, 84003
McFarland Clinic, P. C.
Ames, Iowa, 50010
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
Cancer Center at Providence Alaska Medical Center
Anchorage, Alaska, 99519-6604
Rose Ramer Cancer Clinic at Anderson Area Medical Center
Anderson, South Carolina, 29621
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Fox Valley Hematology and Oncology - East Grant Street
Appleton, Wisconsin, 54911-3496
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Cancer Care at Our Lady of Bellefonte Hospital
Ashland, Kentucky, 41101
Sturdy Memorial Hospital
Attleboro, Massachusetts, 02703
Auburn Regional Center for Cancer Care
Auburn, Washington, 98002
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Aurora, Colorado, 80045
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
St. Joseph Hospital Community Cancer Center
Bellingham, Washington, 98225
St. Charles Medical Center - Bend
Bend, Oregon, 97701
Green Mountain Oncology Group
Bennington, Vermont, 05201
Southwestern Vermont Regional Cancer Center
Bennington, Vermont, 05201
Alta Bates Comprehensive Cancer Center
Berkeley, California, 94704
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, 18015
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Deaconess Billings Clinic Cancer Center
Billings, Montana, 59107-5100
Deaconess Billings Clinic - Downtown
Billings, Montana, 59107-7000
St. Joseph Medical Center
Bloomington, Illinois, 61701
Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center
Boca Raton, Florida, 33486
St. Luke's Mountain States Tumor Institute - Boise
Boise, Idaho, 83712
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Cancer Center of Boston - Chestnut Hill
Boston, Massachusetts, 02120
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts, 02135-2997
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Internal Medicine Associates of Bozeman
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Peninsula Medical Center
Burlingame, California, 94010
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Community Hospital
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
University Hospitals Ireland Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Saint Francis Medical Center
Cape Girardeau, Missouri, 63701
Memorial Hospital
Carthage, Illinois, 62321
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital Regional Cancer Center
Centralia, Washington, 98531-9027
Cancer Center of Kansas, P.A. - Chanute
Chanute, Kansas, 66720
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Martha Jefferson Hospital Cancer Care Center
Charlottesville, Virginia, 22901
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
United Hospital Center
Clarksburg, West Virginia, 26301
Huron Hospital Cancer Care Center
Cleveland, Ohio, 44112
Euclid Hospital
Cleveland, Ohio, 44119
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Memorial Hospital
Colorado Springs, Colorado, 80909
John B. Amos Community Cancer Center
Columbus, Georgia, 31904
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Mount Diablo Regional Cancer Center
Concord, California, 94524-4110
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Heartland Oncology & Hematology
Council Bluffs, Iowa, 51503
Medical City Dallas Hospital
Dallas, Texas, 75230
Presbyterian Hospital of Dallas
Dallas, Texas, 75231
Praxair Cancer Center at Danbury Hospital
Danbury, Connecticut, 06810
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Halifax Medical Center
Daytona Beach, Florida, 32115
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, P.A. - Dodge City
Dodge City, Kansas, 67801
Seacoast Cancer Center at Wentworth-Douglass Hospital
Dover, New Hampshire, 03820
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
Oncology Hematology Associates of Northern Pennsylvania, P.C. at Hahne Regional Cancer Center
DuBois, Pennsylvania, 15801
Easton Regional Cancer Center at Easton Hospital
Easton, Pennsylvania, 18042
Luther Midlelfort Hospital
Eau Claire, Wisconsin, 54702
Midelfort Clinic - Luther
Eau Claire, Wisconsin, 54703-1510
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
Eden, North Carolina, 27288
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Center for Cancer Medicine and Blood Disorders, PA
El Paso, Texas, 79902
Sherman Hospital
Elgin, Illinois, 60120
Vince Lombardi Cancer Center - Elkhorn
Elkhorn, Wisconsin, 53121
Eureka Community Hospital
Eureka, Illinois, 61530
San Juan Regional Cancer Center
Farmington, New Mexico, 87401-5631
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
McLeod Regional Medical Center
Florence, South Carolina, 29501
Front Range Cancer Specialists
Fort Collins, Colorado, 80524
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Broward General Medical Center Cancer Center
Fort Lauderdale, Florida, 33316
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46815
Fremont Memorial Hospital
Fremont, Ohio, 43420
California Cancer Center - Woodward Park Office
Fresno, California, 93720
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Virginia K. Crosson Cancer Center at St. Jude Medical Center
Fullerton, California, 92835
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0232
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Medical and Surgical Specialists, L L C
Galesburg, Illinois, 61401
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Delnor Community Hospital - Geneva
Geneva, Illinois, 60134
Banner Thunderbird Medical Center
Glendale, Arizona, 85306
Adirondack Cancer Care - Glens Falls
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Wayne Radiation Oncology
Goldsboro, North Carolina, 27534
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Mercy Medical Center
Grand Rapids, Michigan, 49503
Spectrum Health Cancer Care - Butterworth Campus
Grand Rapids, Michigan, 49503
Metropolitan Hospital
Grand Rapids, Michigan, 49506
Big Sky Oncology
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1199
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
CCOP - Greenville
Greenville, South Carolina, 29615
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Mason District Hospital
Havana, Illinois, 62644
Saint Rose Hospital
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, 60521
Holland Community Hospital
Holland, Michigan, 49423
Hopedale Medical Complex
Hopedale, Illinois, 61747
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030-4009
Baylor University Medical Center - Houston
Houston, Texas, 77030
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio, 44131
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
Joliet Oncology Hematology Associates, Limited - West
Joliet, Illinois, 60435
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazooaa, Michigan, 49001
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, 66160-7357
CCOP - Kansas City
Kansas City, Missouri, 64131
Good Samaritan Health Systems
Kearney, Nebraska, 68848-1990
Kenton Oncology, Incorporated
Kenton, Ohio, 43326
Keesler Medical Center - Keesler Air Force Base
Kessler Air Force Base, Mississippi, 39534
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas, P.A. - Kingman
Kingman, Kansas, 67068
Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
Kingsport, Tennessee, 37662
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
La Grange Memorial Hospital
La Grange, Illinois, 60525
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236
Haematology-Oncology Associates of Ohio and Michigan, P.C.
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
St. Mary Regional Cancer Center
Langhorne, Pennsylvania, 19047
New York Oncology Hematology, P.C.
Latham, New York, 12110
Central Maine Medical Center
Lewiston, Maine, 04240
Central Baptist Hospital
Lexington, Kentucky, 40503-9985
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Logan Regional Hospital
Logan, Utah, 84321
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California, 92354
McKee Medical Center
Loveland, Colorado, 80539
UMC Southwest Cancer and Research Center
Lubbock, Texas, 79415-3364
McDonough District Hospital
Macomb, Illinois, 61455
Medical Center of Central Georgia
Macon, Georgia, 31208
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Upper Michigan Cancer Center at Marquette General Hospital
Marquette, Michigan, 49855
Northwest Ohio Oncology Center
Maumee, Ohio, 43537
St. Luke's Hospital
Maumee, Ohio, 43537
Hillcrest Cancer Center at Hillcrest Hospital
Mayfield Heights, Ohio, 44124
Caritas Holy Family Hospital
Methuen, Massachusetts, 01844
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middletown Regional Hospital
Middletown, Ohio, 45044
MidMichigan Medical Center - Midland
Midland, Michigan, 48670
Eastern Montana Cancer Center
Miles City, Montana, 59301
Medical Consultants, Limited
Milwaukee, Wisconsin, 53215
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Mobile Infirmary Medical Center
Mobile, Alabama, 36652-2144
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital System
Monroe, Michigan, 48162
Montrose Memorial Hospital Cancer Center
Montrose, Colorado, 81401
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Hackley Hospital
Muskegon, Michigan, 49443
Long Island Jewish Medical Center
New Hyde Park, New York, 11042
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas, P.A. - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Southwest Virginia Regional Cancer Center
Norton, Virginia, 24273
Caritas Norwood Hospital
Norwood, Massachusetts, 02062
Highland General Hospital at St. George's University School of Medicine
Oakland, California, 94602
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Summit Medical Center
Oakland, California, 94609
McKay-Dee Hospital Center
Ogden, Utah, 84403
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
Capital Medical Center
Olympia, Washington, 98507
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
Olympia Fields, Illinois, 60461
Methodist Cancer Center at Methodist Hospital - Omaha
Omaha, Nebraska, 68114
East Alabama Medical Center
Opelika, Alabama, 36801-5452
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, 92868
Florida Oncology Associates
Orange Park, Florida, 32073
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Florida Hospital Cancer Institute at Florida Hospital Orlando
Orlando, Florida, 32803-1273
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology Hematology Associates of Central Illinois - Ottawa
Ottawa, Illinois, 61350
Ottumwa Regional Health Center Cancer Center
Ottumwa, Iowa, 52501
Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital
Parkersburg, West Virginia, 26102
Cancer Center of Kansas, P.A. - Parsons
Parsons, Kansas, 67357
Cancer Treatment Center at Pekin Hospital
Pekin, Illinois, 61554
West Florida Cancer Institute at West Florida Hospital - Pensacola
Pensacola, Florida, 32514
Proctor Hospital
Peoria, Illinois, 61614
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61615
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Northern Michigan Hospital
Petoskey, Michigan, 49770
Banner Good Samaritan Medical Center
Phoenix, Arizona, 85006
CCOP - Western Regional, Arizona
Phoenix, Arizona, 85006
Mount Carmel Regional Cancer Center
Pittsburg, Kansas, 66762
Allegheny Cancer Center at Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Valley Care Medical Center
Pleasanton, California, 94588
St. Joseph Mercy Hospital
Pontiac, Michigan, 48341-2985
Mercy Hospital
Portland, Maine, 04101
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Institute of Oncology at Vilnius University
Portland, Oregon, 97227
Cancer Center of Kansas, P.A. - Pratt
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84604
Good Samaritan Cancer Center
Puyallup, Washington, 98372
All Saints Cancer Center at All Saints Medical Center
Racine, Wisconsin, 53405
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Annie Penn Cancer Center
Reidsville, North Carolina, 27320
Reid Hospital & Health Care Services, Incorporated
Richmond, Indiana, 47374
Valley Hospital - Ridgewood
Ridgewood, New Jersey, 07450
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
Robbinsdale, Minnesota, 55422-2900
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Rutherford Hospital
Rutherfordton, North Carolina, 28139
University of California Davis Cancer Center
Sacramento, California, 95817
Mercy General Hospital
Sacramento, California, 95819
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Health Services
Saint Louis Park, Minnesota, 55416
United Hospital
Saint Paul, Minnesota, 55102
Salem Hospital Regional Cancer Center
Salem, Oregon, 97309-5014
Cancer Center of Kansas, P.A. - Salina
Salina, Kansas, 67042
Utah Cancer Specialists at UCS Cancer Center
Salt Lake City, Utah, 84106
LDS Hospital
Salt Lake City, Utah, 84143
California Pacific Medical Center - California Campus
San Francisco, California, 94118
J.C. Robinson, M.D. Regional Cancer Center
San Pablo, California, 94806
Firelands Regional Medical Center
Sandusky, Ohio, 44870
North Coast Cancer Care, Incorporated
Sandusky, Ohio, 44870
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia, 31403-3089
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98114
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195-6043
North Puget Oncology at United General Hospital
Sedro-Woolley, Washington, 98284
Canada7 sites
Royal Victoria Hospital of Barrie
Barrie, Ontario, L4M 6M2
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V8
Trillium Health Centre - Mississauga Site
Mississauga, Ontario, L5B 1B8
Allan Blair Cancer Centre at Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
St. Joseph's Health Centre - Toronto
Toronto, Ontario, M6R 1B5
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
About this study
Official title: A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether gemcitabine is more effective with or without cetuximab in treating pancreatic cancer.
PURPOSE: This randomized phase III trial is studying giving gemcitabine together with cetuximab to see how well it works compared to giving gemcitabine alone as first-line therapy in treating patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas.
Read the detailed description
OBJECTIVES:
- Compare the overall survival of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas treated with gemcitabine and cetuximab vs gemcitabine alone.
- Compare the time to treatment failure in patients treated with these regimens.
- Estimate the percentage of patients with epidermal growth factor receptor (EGFR) tumor expression in patients treated with these regimens.
- Compare the overall survival of patients in the EGFR-positive subset treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the total response rate (confirmed and unconfirmed complete and partial response) in patients with measurable disease treated with these regimens.
- Compare the patient report of pain and quality of life of patients treated with these regimens.
OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified according to disease status (locally advanced unresectable vs metastatic), Zubrod performance status (0 or 1 vs 2), and prior pancreatectomy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22 and gemcitabine IV over 30 minutes on days 1, 8, 15, and 22 for course 1 and days 1, 8, and 15 for all subsequent courses.
- Arm II: Patients receive gemcitabine as in arm I. In both arms, courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, before each course, and at the end of study therapy.
Patients are followed every 6 months for 2 years and then annually for 1 year.
PROJECTED ACCRUAL: A total of 704 patients (352 per treatment arm) will be accrued for this study within 5 years.
- Conditions
- Pancreatic Cancer
- Being tested
- cetuximab, gemcitabine hydrochloride
- Keywords
- adenocarcinoma of the pancreas, stage III pancreatic cancer, stage IV pancreatic cancer
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cetuximabBiological
Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles
1000mg/m2 IV over 30 minutes
| Study group | Role | What they receive |
|---|---|---|
| gemcitabine hydrochloride + IMC-C225 | Experimental | Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles. Receives: Biological: cetuximab; Drug: gemcitabine hydrochloride |
| gemcitabine hydrochloride alone | Experimental | gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles. Receives: Drug: gemcitabine hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival comparison between treatment groups
Measured: every 4 weeks for 3 years
Secondary outcomes (6)
Response rate comparison between treatment groups as measured by RECIST and radiological evaluation at every other course
Measured: every 9 weeks until progression
Time to treatment failure comparison between groups from registration to first observation of progressive disease, symptomatic deterioration, or death
Measured: every 4 weeks while on treatment
Percentage of patients with EGFR tumor expression and compare overall survival of patients in the EGFR subset
Measured: every 4 weeks for 3 years
Toxicity profile comparison of patients treated with 2 regimens and measured until 30 days after completion of study treatment
Measured: every 4 weeks while on treatment
Total response rate comparison between treatment groups in the subset of patients with measurable disease by RECIST at every other course
Measured: every 9 weeks until progression
Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment
Measured: every 4 weeks while on treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2004 (estimated)
- Study startJan 2004
- Primary completionMay 2007
- Study completionApr 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 766 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B, NCIC Clinical Trials Group
- Responsible party
- Sponsor
- Investigators
- Philip A. Philip, MD, PhD, FRCP, Study chair, Barbara Ann Karmanos Cancer InstituteEileen O'Reilly, MD, Study chair, Memorial Sloan Kettering Cancer CenterRalph PW Wong, MD, FRCPC, Study chair, CancerCare Manitoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00075686
- Sponsor's protocol ID
- CDR0000347414
- Other IDs
- S0205, CALGB-S0205, CAN-NCIC-PAC1, U10CA032102
- Status last verified
- Nov 2015
- First submitted
- 9 Jan 2004
- Last updated
- 17 Nov 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Philip PA, Benedetti J, Fenoglio-Preiser C, et al.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA4509, 2007.
Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6.
PubMed 20606093
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
- ClinicalTrials.gov ID
- NCT00075686
- Acronym / sponsor ID
- CDR0000347414
- Conditions
- Pancreatic Cancer
- Keywords
- adenocarcinoma of the pancreas, stage III pancreatic cancer, stage IV pancreatic cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 766 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B, NCIC Clinical Trials Group
- Study start
- Jan 2004
- Primary completion
- May 2007 (actual)
- Study completion
- Apr 2009 (actual)
- First posted
- 13 Jan 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether gemcitabine is more effective with or without cetuximab in treating pancreatic cancer.
PURPOSE: This randomized phase III trial is studying giving gemcitabine together with cetuximab to see how well it works compared to giving gemcitabine alone as first-line therapy in treating patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas.
Detailed description
OBJECTIVES:
- Compare the overall survival of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas treated with gemcitabine and cetuximab vs gemcitabine alone.
- Compare the time to treatment failure in patients treated with these regimens.
- Estimate the percentage of patients with epidermal growth factor receptor (EGFR) tumor expression in patients treated with these regimens.
- Compare the overall survival of patients in the EGFR-positive subset treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the total response rate (confirmed and unconfirmed complete and partial response) in patients with measurable disease treated with these regimens.
- Compare the patient report of pain and quality of life of patients treated with these regimens.
OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified according to disease status (locally advanced unresectable vs metastatic), Zubrod performance status (0 or 1 vs 2), and prior pancreatectomy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22 and gemcitabine IV over 30 minutes on days 1, 8, 15, and 22 for course 1 and days 1, 8, and 15 for all subsequent courses.
- Arm II: Patients receive gemcitabine as in arm I. In both arms, courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, before each course, and at the end of study therapy.
Patients are followed every 6 months for 2 years and then annually for 1 year.
PROJECTED ACCRUAL: A total of 704 patients (352 per treatment arm) will be accrued for this study within 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| gemcitabine hydrochloride + IMC-C225 | Experimental | Biological: cetuximab, Drug: gemcitabine hydrochlorideLoading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles. |
| gemcitabine hydrochloride alone | Experimental | Drug: gemcitabine hydrochloridegemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cetuximabLoading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles | Biological | gemcitabine hydrochloride + IMC-C225 |
| gemcitabine hydrochloride1000mg/m2 IV over 30 minutes | Drug | gemcitabine hydrochloride + IMC-C225, gemcitabine hydrochloride alone |
Primary outcome
Overall survival comparison between treatment groups
Time frame: every 4 weeks for 3 years
6 secondary outcomes
Response rate comparison between treatment groups as measured by RECIST and radiological evaluation at every other course
Time frame: every 9 weeks until progression
Time to treatment failure comparison between groups from registration to first observation of progressive disease, symptomatic deterioration, or death
Time frame: every 4 weeks while on treatment
Percentage of patients with EGFR tumor expression and compare overall survival of patients in the EGFR subset
Time frame: every 4 weeks for 3 years
Toxicity profile comparison of patients treated with 2 regimens and measured until 30 days after completion of study treatment
Time frame: every 4 weeks while on treatment
Total response rate comparison between treatment groups in the subset of patients with measurable disease by RECIST at every other course
Time frame: every 9 weeks until progression
Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment
Time frame: every 4 weeks while on treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2015.
- Results publicationPhilip PA, Benedetti J, Fenoglio-Preiser C, et al.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA4509, 2007.
- Derived from this study: PubMed 20606093Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6.
Related trials for Pancreatic Cancer
Active, not recruitingPhase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumor
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philip A. Philip, MD, PhD, FRCP study chair
Barbara Ann Karmanos Cancer Institute
Eileen O'Reilly, MD study chair
Memorial Sloan Kettering Cancer Center
Ralph PW Wong, MD, FRCPC study chair
CancerCare Manitoba
389 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing cetuximab and gemcitabine hydrochloride in people with Pancreatic Cancer, run by SWOG Cancer Research Network at 389 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 389 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival comparison between treatment groups (time frame: every 4 weeks for 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00075686, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2015; AzTrials last refreshed its copy on 7 Nov 2026.